4629 related articles for article (PubMed ID: 6374238)
21. Plasminogen activators and inhibitor type-1 in alveolar osteitis.
Serratì S; Margheri F; Bruschi S; D'Alessio S; Pucci M; Fibbi G; Tonelli P; Del Rosso M
Eur J Oral Sci; 2006 Dec; 114(6):500-3. PubMed ID: 17184232
[TBL] [Abstract][Full Text] [Related]
22. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
Nip J; Rabbani SA; Shibata HR; Brodt P
J Clin Invest; 1995 May; 95(5):2096-103. PubMed ID: 7537755
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification.
Nielsen LS; Andreasen PA; Grøndahl-Hansen J; Huang JY; Kristensen P; Danø K
Thromb Haemost; 1986 Apr; 55(2):206-12. PubMed ID: 3520936
[TBL] [Abstract][Full Text] [Related]
24. Spitz naevi may express components of the plasminogen activation system.
Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
[TBL] [Abstract][Full Text] [Related]
25. Immunological characterization of plasminogen activators in human mixed saliva.
Kjaeldgaard A; Kjaeldgaard M
Acta Physiol Scand; 1986 Mar; 126(3):443-7. PubMed ID: 3515850
[TBL] [Abstract][Full Text] [Related]
26. Content and characterization of plasminogen activators in human lung tumors and normal lung tissue.
Markus G; Takita H; Camiolo SM; Corasanti JG; Evers JL; Hobika GH
Cancer Res; 1980 Mar; 40(3):841-8. PubMed ID: 7193515
[TBL] [Abstract][Full Text] [Related]
27. Plasminogen activator content of human colon tumors and normal mucosae: separation of enzymes and partial purification.
Corasanti JG; Celik C; Camiolo SM; Mittelman A; Evers JL; Barbasch A; Hobika GH; Markus G
J Natl Cancer Inst; 1980 Aug; 65(2):345-51. PubMed ID: 6931252
[TBL] [Abstract][Full Text] [Related]
28. Secretion of plasminogen activators by human colorectal and gastric tumor explants.
Harvey SR; Lawrence DD; Madeja JM; Abbey SJ; Markus G
Clin Exp Metastasis; 1988; 6(6):431-50. PubMed ID: 3409559
[TBL] [Abstract][Full Text] [Related]
29. Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas.
Björlin G; Ljungnér H; Wennerberg J; Astedt B
Acta Otolaryngol; 1987; 104(5-6):568-72. PubMed ID: 3434279
[TBL] [Abstract][Full Text] [Related]
30. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
Nishida Y; Hayashi Y; Imai Y; Itoh H
Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous determination of free tissue-type and free urokinase-type plasminogen activators in biological fluids by a solid-phase immunoassay.
Kuo BS; Bjornsson TD
Anal Biochem; 1993 Feb; 209(1):70-8. PubMed ID: 8465964
[TBL] [Abstract][Full Text] [Related]
32. High tPA-expression in primary melanoma of the limb correlates with good prognosis.
Ferrier CM; Suciu S; van Geloof WL; Straatman H; Eggermont AM; Koops HS; Kroon BB; Lejeune FJ; Kleeberg UR; van Muijen GN; Ruiter DJ
Br J Cancer; 2000 Nov; 83(10):1351-9. PubMed ID: 11044361
[TBL] [Abstract][Full Text] [Related]
33. Evidence for a role of the plasminogen activator--plasmin system in corneal ulceration.
Berman M; Leary R; Gage J
Invest Ophthalmol Vis Sci; 1980 Oct; 19(10):1204-21. PubMed ID: 6252112
[TBL] [Abstract][Full Text] [Related]
34. Optical zymography for specific detection of urokinase plasminogen activator activity in biological samples.
Law B; Hsiao JK; Bugge TH; Weissleder R; Tung CH
Anal Biochem; 2005 Mar; 338(1):151-8. PubMed ID: 15707946
[TBL] [Abstract][Full Text] [Related]
35. Prognostic role of urokinase-type plasminogen activator in human gliomas.
Hsu DW; Efird JT; Hedley-Whyte ET
Am J Pathol; 1995 Jul; 147(1):114-23. PubMed ID: 7604873
[TBL] [Abstract][Full Text] [Related]
36. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
37. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.
Wilson MJ; Ludowese C; Sinha AA; Estensen RD
Prostate; 1996 Apr; 28(4):239-50. PubMed ID: 8602400
[TBL] [Abstract][Full Text] [Related]
38. In vitro plasminogen activator activity in human brain tumors.
Tucker WS; Kirsch WM; Martinez-Hernandez A; Fink LM
Cancer Res; 1978 Feb; 38(2):297-302. PubMed ID: 620402
[TBL] [Abstract][Full Text] [Related]
39. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
de Vries TJ; Quax PH; Denijn M; Verrijp KN; Verheijen JH; Verspaget HW; Weidle UH; Ruiter DJ; van Muijen GN
Am J Pathol; 1994 Jan; 144(1):70-81. PubMed ID: 8291613
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system.
Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD
Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
